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Our previous studies suggest that a lack of RUNX3 function is causally related to the genesis and progression of human gastric cancer.
This study was conducted to determine whether alteration of RUNX3 gene expression could be detected in the normal-looking
gastric remnant mucosa, and to ascertain any difference in the potential of gastric carcinogenesis between the anastomotic site and
other areas in the remnant stomach after distal gastrectomy for peptic ulcer (RB group) or gastric cancer (RM group), by analysing
RUNX3 expression with special reference to topography. A total of 89 patients underwent distal gastrectomy for gastric cancer from
the intact stomach (GCI group) and 58 patients underwent resection of the remnant stomach for gastric cancer (RB group: 34 cases,
RM group: 24 cases). We detected RUNX3 and gene promoter methylation by in situ hybridisation, quantitative reverse
transcriptase–polymerase chain reaction (RT–PCR), and methylation-specific PCR. The interval between the initial surgery and
surgery for remnant gastric cancer (interval time) was 10.4 years in the RM group, and 27.5 years in the RB group. Cancers in the RB
group were significantly more predominant in the anastomosis area (Po0.05). Within the tumour, downregulation of RUNX3
expression ranged from 74.7 to 85.7% in the three groups. The rate of downregulation of RUNX3 of adjacent mucosa was 39.2% (11
in 28 cases) in RB and 47.6% (10 in 21 cases) in RM, which are significantly higher than that of the GCI group (19.5%, 17 in 87 cases).
In noncancerous mucosa of the remnant stomach in the RB group, RUNX3 expression decreased more near the anastomosis area. In
the RM group, however, there were no significant differences in RUNX3 expression by sampling location. Based on RUNX3
downregulation and clinical features, residual stomach mucosa of the RM group would have a higher potential of gastric
carcinogenesis compared to the RB or GCI group. Gastric stump mucosa of the RB group has higher potential especially than other
areas of residual stomach mucosa. Measurement of RUNX3 expression and detection of RUNX3 methylation in remnant gastric
mucosa may estimate the forward risk of carcinogenesis in the remnant stomach.
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Our previous studies suggest that lack of RUNX3 function is
causally related to the genesis and progression of human gastric
cancer, indicating that RUNX3 is a novel tumour suppressor (Li
et al, 2002). RUNX3 shows remarkable downregulation in gastric
cancers compared to the surrounding mucosa, and the percentage
of downregulation increases as the cancer stage progresses.
Furthermore, RUNX3 expression is reduced in intestinal metapla-
sia, a precancerous state, compared with normal mucosa (Li et al,
2002), suggesting that downregulation of RUNX3 occurs at the
early stages of gastric carcinogenesis, and that loss of RUNX3
expression increases the potential for gastric carcinogenesis.
Patients with a remnant stomach have been thought to be more
susceptible to the development of cancer than the general
population, perhaps related to duodenogastric reflux, denervation,
and Helicobacter pylori infection (Toftgaard, 1989; Kaminishi et al,
1995; Miwa et al, 1993, 1995; Johannesson et al, 2003). In the long
term after partial gastrectomy, atrophic gastritis, intestinal
metaplasia, and dysplasia are frequent, and these changes are
thought to be precancerous (Nakanishi et al, 1993; Safatle-Ribeiro
et al, 1996; Tanigawa et al, 2000; Nishizawa et al, 2002). There are
clinicopathologic differences between remnant gastric cancers
arising after distal gastrectomy for peptic ulcer (RB group) vs
gastric cancer (RM group). We hypothesised that the pathogenesis
of the RM group, including its genetic background, differs from
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sthe RB group, but few studies have investigated these issues
(Fujihara et al, 1996; Baba et al, 2001; Matsui et al, 2001).
The current investigation was undertaken to determine whether
alterations of RUNX3 gene expression could be detected in
normal-looking gastric remnant mucosa. We ascertained differ-
ences in the potential of gastric carcinogenesis between the
anastomotic site and other areas in the remnant stomach after
distal gastrectomy for peptic ulcer (RB group) or gastric cancer
(RM group), by analysing RUNX3 with special reference to
topography.
MATERIALS AND METHODS
Patients
We enrolled 89 patients with gastric cancer in the intact stomach
(GCI group), and 58 patients with remnant gastric cancer after
distal gastrectomy (RGC group). All GCI patients underwent distal
gastrectomy for gastric cancer from the intact stomach between
January 2001 and January 2002 at the Department of Digestive
Surgery, Kyoto Prefectural University of Medicine. The RGC
patients underwent resection of the remnant stomach for gastric
cancer between January 1993 and September 2003 at the
Department of Digestive Surgery, Kyoto Prefectural University of
Medicine, the Department of Surgery, Kyoto First Red Cross
Hospital, and the Department of Surgery, Kyoto Second Red Cross
Hospital. The RGC group was divided into the RB group, 34
patients who initially underwent distal gastrectomy for benign
peptic ulcer, and the RM group, 24 patients who underwent distal
gastrectomy for primary gastric cancer. The Japanese General
Rules for Gastric Cancer were used for pathologic diagnosis and
classification of tumours (Japanese Gastric Cancer Association,
1999). The following factors were compared between groups: age,
gender, depth of invasion, histologic type, lymph node spread, and
stage. The following factors were compared between the RB and
RM groups: interval between initial surgery and surgery for
remnant gastric cancer (interval time), method of reconstruction
after primary resection, and tumour location.
For the present study, we selected remnant gastric cancer cases
in which cancers developed 5 or more years after initial distal
gastrectomy for either peptic ulcer or gastric cancer, to avoid
recurrent cancer cases.
In situ hybridisation
Formalin-fixed, paraffin-embedded tissue blocks were cut into
5-mm-thick sections in RNase-free water and mounted on slides.
In situ hybridisation was performed as described previously
(Satake et al, 1995) using sense and antisense DIG-labelled probes
consisting of RUNX3 nucleotides 550–848 (accession number
Z35278).
RNA probe was synthesised with T7 RNA polymerase, using a
digoxigenin (DIG) RNA Labeling Kit (Boehringer Mannheim).
After proteinase K digestion (18mgml
 1), the sections were
postfixed with 4% (wv
 1) paraformaldehyde in phosphate-
buffered saline for 10min and treated with 0.1 M triethanola-
mine-HCl (pH 8.0) for 1min. Following acetylation for 10min, the
sections were dehydrated, air-dried and then incubated overnight
at 501C in hybridisation buffer composed of 50% formamide,
10mM Tris-HCl (pH 7.5), 1mgml
 1 yeast tRNA (Sigma), 1 
Denhalt’s solution (Sigma), 10% PEG6000, 600mM NaCl, 0.25%
SDS, 1mM EDTA, and 0.2mgml
 1 probe. After hybridisation, the
sections were washed at 451C for 1h in 50% formamide and
2 SSC, and digested with 20mgml
 1 RNase (Sigma) in 10mM
Tris-HCl (pH 8.0) and 500mM NaCl at 371C for 30min. Hybridised
DIG-labelled probes were visualised with a Nucleic Acid Detection
Kit (Boehringer Mannheim).
As RUNX3 expression was weak at the stem cell zone of normal
gastric mucosa, stained cells represented about 50% of epithelial
cells in normal mucosa, and expressed in surface mucous cells and
chief cells (Li et al, 2002). In the present study, we counted 1000
cells of the tumour or adjacent noncancerous epithelial cells to
calculate the percentage of stained cells. We have counted the
RUNX3-positive cells per gland base. RUNX3-positive cells in
normal gland of different five areas were calculated and averaged.
When it was not possible to count RUNX3-positive cells per gland
base, we counted cells of the whole mucosal layer in each area.
After counting more than 1000 epithelial cells, we calculated the
percentage of positive cells, using all data from the three different
zones. In the remnant mucosa, a percentage of RUNX3-positive
cells less than 30% of that of the fundic gland was accepted as the
criterion for downregulation of RUNX3 in remnant gastric
mucosa.
Quantitative reverse transcriptase–polymerase chain
reaction
cDNA was produced from total RNA by using a Superscript
preamplification system (BRL, Bethesda, MD, USA) and following
the procedures suggested by the manufacturer. RNA was heated to
701C for 10min in 14ml of duethylpyrocarbonate-treated water
containing 0.5mg oligo (dT). Synthesis buffer (10 ), 2ml1 0 m M
dNTP mix, 2ml 0.1 M DTT, and reverse transcriptase (Superscript
RT; 200Uml
 1) were added to the sample. The resulting reaction
mixture was incubated at 421C for 50min, and the reaction was
terminated by incubating the mixture at 901C for 5min.
Quantitative PCR was performed using real-time ‘Taqman TM’
technology and analysed on a Model 5700 Sequence Detector
(Applied Biosystems Corp., Foster City, CA, USA) as described
previously (Sakakura et al, 2004).
RUNX3 reverse transcriptase-polymerase chain reaction (RT–
PCR) primers are 50-AAG CAC AGC CAT CAG GAT TCA-30 and
50-TGG ACA TGC TTG CGG ATA TAA G-30. Hybridization probes,
which bind to PCR products, were labelled with a reporter dye, FAM
on the 50 nucleotide and a quenching dye TAMRA, on the 30
nucleotide. The sequence of hybridisation probe is RUNX3: 50-(FAM)
CAT CTG GAA CTT CTC CTG GTC TCT CAG C (TAMRA)-30.
In total, 50ml reactions contained: 1.25U Amp-Taq DNA
polymerase, 1  PCR reaction buffer, 180ng of each primer,
200mM dNTP, 400mM dNTP, 100nM Taqman probe, and 0.5U
Amplirase (Applied Biosystems Corp.). The Ct value correspond-
ing to the cycle number at which the fluorescence emission
monitored in real time reaches a threshold of 10 standard
deviations above the mean base line emission from cycle 1 to 40
was measured in serial dilutions of control cDNA, analysed for
each target. These target genes were served as standard curves
from which to determine the rate of changes of Ct value. Cycling
parameters were 2min at 501C, and 10min at 951C followed by 40
cycles of 15s at 951C and 1min at 601C.
To minimise the errors arising from the varidation in the
amount of starting RNA among samples, amplification of b-actin
mRNA was performed as an internal reference against which other
RNA values could be normalised. Normalised results were
expressed as the ratio of copies of each gene to copies of the
b-actin gene.
Methylation-specific PCR
Methylation-specific PCR (MSP) was performed as reported
previously (Herman et al, 1993). Briefly, genomic DNA denatured
by NaOH was treated with sodium bisulphite and purified. The
DNA was subjected to PCR using the following primers: primer set
for untreated DNA: 50-GAG GGG CGG CCG CAC GCG GG-30,5 0-
CGG CCG GCG CGG GCG CCT CC-30; primer set for detecting
methylated DNA: 50-TTA CGA GGG GCG GTC GTA CGC GGG-30,
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detecting unmethylated DNA: 50-TTA TGA GGG GTG GTT GTA
TGT GGG-30,5 0-AAA ACA ACC AAC ACA AAC ACC TCC-30.
Methylated nucleotides were verified by sequencing the PCR
product.
Statistical analysis
The results are presented as mean7s.d. values. Statistical
comparisons between groups were performed using the Krus-
kal–Wallis test, the Mann–Whitney U-test, or Student’s t-test by
computer software StatMate (ATMS, Tokyo, Japan). Statistical
significance was defined as a P-value less than 0.05.
RESULTS
Clinicopathologic variables
The clinicopathologic characteristics of patients in the GCI, RB,
and RM groups are listed in Table 1. Age, gender, histologic type,
and lymph node metastasis showed no significant differences
between the three groups. The RB and RM groups had significantly
more invasive tumours and more advanced stage cancers than the
GCI group. Interval time and reconstruction at primary surgery
and tumour location of the RB and RM groups are listed in Table 2.
The interval time between primary surgery and later appearance of
cancer was 27.5 years for RB and 10.4 years for RM. At the initial
operation in the RB group, Billroth-II reconstructions were
significantly more common than Billroth-I. By contrast, RM group
patients had more Billroth-I reconstructions. In the RB group,
remnant gastric cancers developed predominantly in the anasto-
mosis areas and suture lines (25 in 34 cases, 73.5%). In contrast, in
the RM group, there were no significant differences in tumour
location.
RUNX3 downregulation in remnant stomach cancers and
surrounding mucosa analysed by in situ hybridisation
Figure 1 shows in situ hybridisation of RUNX3 mRNA in a
remnant stomach cancer specimen. Panels A and B of Figure 1
show a surgically resected specimen of remnant stomach cancer
tissue surrounded by normal mucosa of lower magnification
( 40). RUNX3 expression can be clearly detected within the
normal gastric epithelial cell layer, but only weakly in the cancer
tissue (Figure 1A and B). The pattern is more clearly visible at
higher magnification. The corresponding regions in Figure 1C, E,
and G are shown in Figure 1D, F, and H, clearly demonstrating that
RUNX3 expression is mainly restricted to the normal epithelial
cells and not evident in the surrounding mesenchymal cells
( 400). Figure 1C shows cancer cells of well-differentiated
adenocarcinoma with irregularly shaped atypical tubular struc-
tures lined by pleomorphic cells and enlarged, irregular, vesicular
nuclei. Figure 1D demonstrates that cancer tissue does not
significantly express RUNX3. In contrast, intensive RUNX3
expression is observed in Figure 1E and F. Intestinal metaplasia
shows downregulation of RUNX3 (Figure 1G and H). The result of
a negative control is shown when the antisense probe is replaced
by a sense probe (data not shown). Our additional experiments
have shown that in situ hybridisation with b-actin as a positive
control shows the positive staining of the whole area of mucosa
(data not shown).
Gastric stump mucosa of the RB group showed significant
downregulation of RUNX3 compared to other areas (distant areas
from gastric stump) as shown in Figure 2. Furthermore, gastric
cystica polyposa (GCP) was frequently observed in gastric stump
mucosa and typical data of RUNX3 expression in these lesions
were analysed by in situ hybridization as shown in Figure 2.
Figure 2B shows significant downregulation of RUNX3 in GCP,
and HE staining of corresponding lesions is shown in Figure 2A. In
both intestinal metaplasia and chronic gastritis, RUNX3 expres-
sion was reduced. RUNX3 expression was decreased to a greater
extent near the anastomosis area in the RB group (Figure 2C and
D). In contrast, RUNX3 expression was observed mainly distant
from the anastomosis area in the RB group (Figure 2E and F).
Table 1 Clinicopathologic characteristics of patients with gastric cancer
from intact stomach (GCI group) and remnant gastric cancer (RB group
and RM group)
GCI (89) RB 34 RM 24 P-value
Age (years) 66.1713.7 66.3710.5 62.779.5 NS
Male:female ratio 62:27 30:4 19:5 NS
Depth of invasion**
m2 3 5 2
sm 28 6 6
pm 6 3 4 0.034
ss 8 7 4
se 20 9 4
si 4 4 4
Histologic type
tub 1 24 12 7
tub 2 15 5 4
por 1 12 4 3
por 2 17 7 4 NS
sig 16 4 5
pap 5 1 1
Lymph node spread
n0 55 22 17
n1 18 4 3 NS
n2 10 4 2
n3 6 2 2
Stage classification*
Ia 47 10 6
Ib 13 4 4
II 9 2 2 0.004
IIIa 7 7 5
IIIb 7 5 2
IV 6 4 5
*Po0.01, **Po0.05, NS: not significant. GCI¼cancer from intact stomach.
RB¼remnant gastric cancer arising after distal gastrectomy for peptic ulcer.
RM¼remnant gastric cancer arising after distal gastrectomy for gastric cancer.
Table 2 Clinical characteristics of the RB and RM groups
RB (34) RM (24) P-value
Interval (years)* 27.5710.5 10.474.1 0.001
Reconstruction at primary surgery*
Billroth I:II 9:25 17:7 0.003
Location of tumour* (Billroth I:II)
Anastomosis 19 (2:17) 6 (3:3)
Suture-line 6 (3:3) 2 (2:0) 0.021
Other 6 (4:2) 15 (11:4)
Wide body 3 (1:2) 1 (1:0)
Interval¼between primary surgery and the appearance of remnant gastric cancer.
*Po0.01, NS: not significant.
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cancers and surrounding mucosa
Informative results were obtained in 87 of 89 GCI cases, 28 of 34
RB cases, and 21 of 24 RM cases. The overall incidence of RUNX3
downregulation in clinical specimens of RM, RB, and GCI cases is
shown in Figure 3. Downregulation of the RUNX3 expression rate
in tumour was 74.7% (65 in 87 cases) in the GCI group, 82.1% (24
in 28 cases) in the RB group, and 85.7% (18 in 21 cases) in the RM
A B
C
E
G
E (normal gland) 
C (Ca.) G (IM)
F (normal gland) 
D (Ca.) H (IM)
D
F
H
Figure 1 In situ hybridisation of RUNX3 mRNA in a remnant gastric cancer specimen. Haematoxylin and eosin staining (A) and in situ hybridisation using
an antisense probe (B). Cancer tissue faces the lumen (upper side). Scale bars are equal to 1mm. Enlargement of boxed regions marked (C–H) in (A) and
(B). (C, D) show cancer cells (Ca.); (E and F) show normal mucosa; and (G and H) show intestinal metaplasia (IM). Scale bars are 100mm.
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(RM, RB, and GCI group) was frequently observed in the same
degree (74.7, 82.1, and 85.7%, respectively). In contrast, the rate of
downregulation of RUNX3 in adjacent mucosa was 39.2% (11 in 28
cases) in RB and 47.6% (10 in 21 cases) in RM, significantly higher
than that of the GCI group (19.5%, 17 in 87 cases).
RUNX3 downregulation in remnant stomach cancers and
surrounding mucosa analysed by quantitative RT–PCR
Gastric mucosa samples were taken from the resected remnant
stomach at 2cm lengths from distal to proximal as shown in Figure
4A and B. Figure 4A shows the surgical specimen of remnant
stomach cancer arising after distal gastrectomy for gastric cancer
reconstructed by Billroth-I procedure (RM group). Figure 4B shows
the surgical specimen of remnant stomach cancer arising after
distal gastrectomy for peptic ulcer reconstructed by Billroth-II
procedure (RB group). We performed quantitative RT–PCR in 12
RB cases and 10 RM cases. We measured RUNX3 expression in 10
cases with normal mucosa as a reference, sampled from the intact
Figure 2 RUNX3 expression in noncancerous remnant gastric mucosa (RB group, Billroth-II reconstruction). (A, B) are gastric cystica polyposa in the
anastomosis area, (C, D) are distal, and (E, F) are proximal. Haematoxylin and eosin staining (A, C, E) and in situ hybridisation using antisense probe (B, D,
F). Mucosa faces the lumen (upper side). Scale bars are 300mm.
GCI group RB group RM  group
D
o
w
n
r
e
g
u
l
a
t
i
o
n
 
r
a
t
e
 
o
f
 
R
U
N
X
3
 
 
e
x
p
r
e
s
s
i
o
n
 
(
%
)
NT NT NT
(P = 0.017) (P = 0.001)
*P < 0.01
(P = 0.004)
*P < 0.01 **P < 0.05
100
80
60
40
20
0
Figure 3 Downregulation rate of RUNX3 expression in mucosa and
tumour in GCI, RB, and RM groups. T; tumour. N; noncancerous adjacent
mucosa.
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in all areas of remnant gastric mucosa in both RB and RM groups
was significantly more decreased than in normal gastric mucosa
(Po0.01). Furthermore, RUNX3 expression was significantly
decreased near the anastomosis area (location a of panel B,
Figure 4) in the RB group compared to other areas (locations b, c,
d, and e of panel B, Figure 4) (Figure 4, panels B and C, Po0.05). In
contrast, in the RM group, there were no significant differences in
RUNX3 expression in the surrounding mucosa for all sampling
locations (Figure 4, panels A and C, locations a, b, c, and d).
Methylation-specific PCR
We performed MSP in 12 RB cases and 10 RM cases. Typical data
for MSP of remnant gastric cancer and adjacent mucosa are shown
in Figure 5A ((M) methylated-sequence-specific PCR, (U) un-
methylated-sequence-specific PCR). Methylation of RUNX3 was
present in 63.6% (14 in 22 cases) of cancers and 27.2% (six in 22
cases) of noncancerous adjacent mucosa, which correlated with
RUNX3 expression. A significant correlation between methylation
status of RUNX3 and RUNX3 expression was observed. In samples
that were negative for RUNX3 expression, C residues in the CpG
dinucleotide within the region were methylated (Figure 5B). In
contrast, in samples positive for RUNX3 expression, none of the C
residues were methylated.
DISCUSSION
In the present study, we noted two significant differential features
between RM and RB groups: tumour location and interval time.
Cancers in the RB group were significantly more predominant in
the anastomosis area, and the interval time in the RM group was
shorter. These clinicopathologic features suggest that residual
stomach mucosa of RM would have higher potential for gastric
carcinogenesis compared to the RB and GCI groups and that
gastric stump mucosa of RB has a higher potential than other parts
of the residual stomach mucosa.
In accordance with clinicopathologic analysis, significant
downregulation of RUNX3 was observed in the whole mucosa of
the RM group and the anastomotic site of the RB group. In the
remnant stomach mucosa, chronic gastritis and intestinal meta-
plasia were intensively observed with downregulation of RUNX3.
Our previous study and others indicate that RUNX3 down-
regulation is frequently observed in chronic gastritis, intestinal
metaplasia, and gastric adenoma in the GCI group (Li et al, 2002;
Kim et al, 2004), which are thought to be precancerous (Safatle-
Ribeiro et al, 1996; Tanigawa et al, 2000; Nishizawa et al, 2002).
In our study, 19.5% of adjacent mucosa of the GCI group
had downregulation of RUNX3 expression. Although there is
no downregulation of RUNX3 in gastric mucosa at the initial
operation for benign peptic ulcer (data not shown), the down-
regulation of RUNX3 in noncancerous mucosa has already
occurred by the time of primary surgery in the RM group
(19.5%), suggesting that the background mucosa of RM has
a high risk of carcinogenesis at the time of primary surgery. In
cases of remnant gastric cancer, the rate of downregulation of
RUNX3 of adjacent mucosa was 39.2% in RB and 47.6% in RM,
which are higher than that of GCI (19.5%). Based on the incidence
of RUNX3 downregulation in background gastric mucosa, it is
suggested that the risk of carcinogenesis in the RB or RM groups is
higher than that of the GCI group. RUNX3 downregulation would
have a causal role in carcinogenesis of the remnant stomach, as
well as GCI.
An increased risk of remnant gastric cancer at the anastomotic
site has been reported (Miwa et al, 1995). ‘Gastric stump carci-
noma’ is primarily recognized as a carcinoma developing in the
gastric remnant after gastrectomy for benign disease (Freedman
and Berne, 1954; Heinzel and Laqua, 1954). The stump carcinoma
was often localised to the anastomosis, known to be the site of
severe duodenogastric reflux. For this reason, the argument
has been made about the role of duodenogastric reflux as an
important causal factor in gastric carcinogenesis. Previous studies
indicate that patients with Billroth-II reconstruction tend to have
cancer development at the anastomotic site, while patients with
Billroth-I reconstruction tend to have cancer development at
nonanastomotic sites (Kondo et al, 1991; Sowa et al, 1993; Baba
et al, 2001; Tanigawa et al, 2002). Our results were similar, but
patients with Billroth-II reconstruction of the RM group had
equivalent rates at both sites. In accordance with tumour location,
RUNX3 expression was more decreased in gastric stump mucosa
in the RB group, and there was no difference in RUNX3 expression
by location in the RM group. Gastric cystica polyposa, which is
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Figure 4 Quantitative RT–PCR of noncancerous mucosa in RB and RM
groups. Resected remnant stomach; RM group, Billroth-I reconstruction
(A). RB group, Billroth-II reconstruction (B). Gastric mucosa samples from
remnant stomach are 2–3cm lengths from distal to proximal (a–d). (C)
Quantitative analysis of tumour and noncancerous mucosa (a–d) in RM
(black bars) and RB groups (white bars). Control; normal gastric mucosa
(fundic glands). Mean7s.d. values.
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development in the remnant stomach, is detected more often at
the anastomotic site of patients with Billroth-II reconstruction
(Koga et al, 1979; Matsuda et al, 1995). Interestingly, RUNX3 is
downregulated in GCP as shown in Figure 2, although it is still
controversial whether GCP is precancerous or not (Littler and
Gleibermann, 1972; Jablokow et al, 1982; Mukaisho et al, 2003).
These findings suggest that methylation and silencing of RUNX3
occurs mostly at the anastomotic site in the RB group, probably
due to bile reflux. The interval time was 27.5 years for the RB
group and 10.4 years in the RM group, similar to previous reports
(Koga et al, 1979; Fujihara et al, 1996; Baba et al, 2001).
Carcinogenesis in RB through bile reflux, denervation, or
Helicobacter pylori infection may take longer than re-emergence
of cancer on RM.
To date, genetic alterations associated with remnant gastric
cancer have included p53, Ki-ras, cyclooxygenase-2, and bcl-2
(Clarke et al, 1997; Yamashita et al, 1998; van Rees et al, 1999; Baba
et al, 2001; Kawabe et al, 2002). However, no reports have
addressed these issues through pathogenesis and genetic changes
of the surrounding mucosa. Few studies have investigated the
genetic differences between RB and RM groups. Baba et al (2001)
compared these groups and reported that p53 mutations and
PCNA overexpression enhanced the proliferative activity of cancer
cells of the RM group (Fukuzawa et al, 1996). Many genetic
changes, including RUNX3 downregulation, could contribute to
the increased potential for gastric carcinogenesis. Further studies
are necessary to clarify this.
In conclusion, based on RUNX3 downregulation and clinical
features, residual stomach mucosa of the RM group has higher
potential for gastric carcinogenesis compared to the RB or GCI
groups. Gastric stump mucosa of the RB group has higher
potential than other areas of residual stomach. Although most
patients with remnant gastric cancer have advanced disease and a
poor prognosis (Sakakura et al, 2004), endoscopy for monitoring
the remnant stomach may contribute to early detection and
improved prognosis (Kikuchi et al, 2003). The measurement of
RUNX3 expression and detection of RUNX3 methylation in
remnant gastric mucosa may estimate the forward risk of
carcinogenesis in the remnant stomach.
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